Termination notice effective period.

No definition available.

Name:	cara_AgreementTerminationNoticeEffectivePeriod
Namespace Prefix:	cara_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Closing prices of company common stock description.

+ References

No definition available.

+ Details

Name:	cara_ClosingPricesOfCompanyCommonStockDescription
Namespace Prefix:	cara_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cost of clinical compound sale related to research and development expense.

+ References

No definition available.

+ Details

Name:	cara_CostOfClinicalCompoundSaleRelatedToResearchAndDevelopmentExpense
Namespace Prefix:	cara_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of combined performance obligations for revenue recognized.

+ References

No definition available.

+ Details

Name:	cara_NumberOfCombinedPerformanceObligationsForRevenueRecognized
Namespace Prefix:	cara_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of days to terminate agreement upon material breach.

+ References

No definition available.

+ Details

Name:	cara_NumberOfDaysToTerminateAgreementUponMaterialBreach
Namespace Prefix:	cara_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of performance obligations for revenue recognized.

+ References

No definition available.

+ Details

Name:	cara_NumberOfPerformanceObligationsForRevenueRecognized
Namespace Prefix:	cara_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential milestone payments receivable.

+ References

No definition available.

+ Details

Name:	cara_PotentialMilestonePaymentsReceivable
Namespace Prefix:	cara_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Premium from sale of stock.

+ References

No definition available.

+ Details

Name:	cara_PremiumFromSaleOfStock
Namespace Prefix:	cara_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue performance obligation upfront payment received.

+ References

No definition available.

+ Details

Name:	cara_RevenuePerformanceObligationUpfrontPaymentReceived
Namespace Prefix:	cara_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Third party cost for clinical development threshold amount.

+ References

No definition available.

+ Details

Name:	cara_ThirdPartyCostForClinicalDevelopmentThresholdAmount
Namespace Prefix:	cara_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:	us-gaap_SharesIssuedPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=cara_LicenseAndMilestoneFeesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cara_CollaborativeRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cara_ClinicalCompoundRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=cara_ViforFreseniusMedicalCareRenalPharmaLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cara_RegulatoryAndCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cara_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cara_TieredCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=cara_MaruishiPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and Licensing Agreements - Additional Information (Detail)		3 Months Ended		9 Months Ended
	May 17, 2018 USD ($) PerformanceObligation $ / shares shares	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) PerformanceObligation	Sep. 30, 2017 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue from contract with customer		$ 5,062,000		$ 7,936,000	$ 911,000
License and Milestone Fees [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue from contract with customer		5,029,000		7,903,000	530,000
Collaborative Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue from contract with customer					313,000
Clinical Compound Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue from contract with customer		33,000		$ 33,000	68,000
Vifor Fresenius Medical Care Renal Pharma Ltd. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of performance obligations for revenue recognized \| PerformanceObligation				2
Non-refundable, non-creditable upfront payment	$ 50,000,000
Common stock, shares issued \| shares	1,174,827
Purchase of common stock value	$ 20,000,000
Purchase common stock per share amount \| $ / shares	$ 17.024
Closing prices of company common stock description	over a pre-determined average closing price of the Company’s common stock.
Premium from sale of stock	$ 5,444,000
Contract liabilities	$ 55,444,000
Number of combined performance obligations for revenue recognized \| PerformanceObligation	1
Number of days to terminate agreement				60 days
Termination notice effective period				12 months
Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Third-party cost for clinical development	$ 20,000,000
Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] \| Maximum [Member] \| Regulatory and Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments receivable	470,000,000
Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] \| Maximum [Member] \| Regulatory Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments receivable	30,000,000
Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] \| Maximum [Member] \| Tiered Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments receivable	$ 440,000,000
Maruishi Pharmaceutical Co., Ltd. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of performance obligations for revenue recognized \| PerformanceObligation				2
Cost of clinical compound related to R&D expense		30,000	$ 0	$ 30,000	61,000
Maruishi Pharmaceutical Co., Ltd. [Member] \| Sub-License Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue from contract with customer					843,000
Maruishi Pharmaceutical Co., Ltd. [Member] \| License and Milestone Fees [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue from contract with customer					530,000
Maruishi Pharmaceutical Co., Ltd. [Member] \| Collaborative Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue from contract with customer					313,000
Maruishi Pharmaceutical Co., Ltd. [Member] \| Clinical Compound Revenue [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue from contract with customer		$ 33,000	$ 0	$ 33,000	$ 68,000